Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Fumoleau

Showing results (21-30 of 152) with videos related to

Pageof 16
Sort By:
European Journal of Cancer (Oxford, England : 1990)|August 1, 1997
Docetaxel in combination with doxorubicin or vinorelbineV Diéras, P Fumoleau, S Kalla, et al.
Anti-Cancer Drugs|August 1, 1996
Taxoids in combination chemotherapy for metastatic breast cancerV Dieras, P Fumoleau, H Bourgeois, et al.
American Journal of Clinical Oncology|July 28, 2001
Epirubicin--docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy studyP Viens, H Roché, P Kerbrat, et al.
Archives Des Maladies Du Coeur Et Des Vaisseaux|November 1, 1983
[Endomyocardial biopsy as a method of surveilling adriamycin cardiac toxicity. 28 biopsies in 26 patients]J B Bouhour, H Petitier, A Y Delajartre, et al.
Cancer Chemotherapy and Pharmacology|November 3, 2011
A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanesM Campone, N Isambert, E Bourbouloux, et al.
Seminars in Oncology|April 1, 1995
Vinorelbine (Navelbine) in the treatment of breast cancer: the European experienceP Fumoleau, T Delozier, J M Extra, et al.
Bulletin Du Cancer|January 1, 1990
[Phase II trial as 2nd line chemotherapy with 5 fluorouracil and cisplatin (5FU-CDDP) for advanced breast cancer]P Fumoleau, P Bastit, D Horner, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1984
Radioimmunoassay of the CA 12 5 antigen in ovarian carcinomas: advantages compared with CA 19-9 and CEAG Ricolleau, J F Chatal, P Fumoleau, et al.
Cancer Chemotherapy and Pharmacology|May 28, 2003
Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancerS Urien, P Fumoleau, M Campone, et al.
Cancer Chemotherapy and Pharmacology|October 13, 2006
Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1-d2-d3) in patients with refractory solid tumorsM Campone, N Isambert, E Bourbouloux, et al.
Pageof 16

Showing results (21-30 of 152) with videos related to

Sort By:
Pageof 16
European Journal of Cancer (Oxford, England : 1990)|August 1, 1997
Docetaxel in combination with doxorubicin or vinorelbineV Diéras, P Fumoleau, S Kalla, et al.
Anti-Cancer Drugs|August 1, 1996
Taxoids in combination chemotherapy for metastatic breast cancerV Dieras, P Fumoleau, H Bourgeois, et al.
American Journal of Clinical Oncology|July 28, 2001
Epirubicin--docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy studyP Viens, H Roché, P Kerbrat, et al.
Archives Des Maladies Du Coeur Et Des Vaisseaux|November 1, 1983
[Endomyocardial biopsy as a method of surveilling adriamycin cardiac toxicity. 28 biopsies in 26 patients]J B Bouhour, H Petitier, A Y Delajartre, et al.
Cancer Chemotherapy and Pharmacology|November 3, 2011
A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanesM Campone, N Isambert, E Bourbouloux, et al.
Seminars in Oncology|April 1, 1995
Vinorelbine (Navelbine) in the treatment of breast cancer: the European experienceP Fumoleau, T Delozier, J M Extra, et al.
Bulletin Du Cancer|January 1, 1990
[Phase II trial as 2nd line chemotherapy with 5 fluorouracil and cisplatin (5FU-CDDP) for advanced breast cancer]P Fumoleau, P Bastit, D Horner, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1984
Radioimmunoassay of the CA 12 5 antigen in ovarian carcinomas: advantages compared with CA 19-9 and CEAG Ricolleau, J F Chatal, P Fumoleau, et al.
Cancer Chemotherapy and Pharmacology|May 28, 2003
Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancerS Urien, P Fumoleau, M Campone, et al.
Cancer Chemotherapy and Pharmacology|October 13, 2006
Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1-d2-d3) in patients with refractory solid tumorsM Campone, N Isambert, E Bourbouloux, et al.
Pageof 16